Exclusive Sublicense Agreement Sample Contracts

Victory Energy Corp – Exclusive Sublicense Agreement (August 24th, 2017)

THIS EXCLUSIVE SUBLICENSE AGREEMENT (this "Agreement") is made and entered into as of the 21st day of August, 2017 (the "Effective Date"), by and between ARMACOR VICTORY VENTURES, LLC, a Delaware limited liability company having its principal place of business at 20505 Crescent Bay Drive, Lake Forest, CA 92630 ("Licensor"), and VICTORY ENERGY CORPORATION, a Nevada corporation having its principal place of business at 3355 Bees Cave Road, Suite 608, Austin, TX 78746 ("Licensee").

Benitec Biopharma LTD/ADR – Exclusive Sublicense Agreement (June 1st, 2017)

This Exclusive Sublicense Agreement (this Agreement) is made and entered into as of the 23rd day of December, 2016 (Effective Date), by and between Benitec Biopharma Limited, a company organized under the laws of Australia with its principal business at 99 Mount Street, North Sydney NSW 2060, Australia (Benitec), and NantWorks, LLC, a Delaware limited liability company with its principal business at 9920 Jefferson Boulevard, Culver City, California 90232 (NantWorks).

Non-Exclusive Sublicense Agreement (August 14th, 2015)

This Non-Exclusive Sublicense Agreement (Agreement) is entered into as of the Effective Date by and between Juno Therapeutics, Inc., a Delaware corporation having its principal place of business at 307 Westlake Avenue North, Suite 300, Seattle, Washington 98109, United States of America (Juno), Novartis Institutes for Biomedical Research, Inc., a Delaware corporation having offices located at 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States of America (Novartis), and The Trustees of the University of Pennsylvania, a nonprofit corporation organized under the laws of Commonwealth of Pennsylvania, United States of America (Penn and, together with Novartis and Juno, the Parties).

Assignment and Option Agreement by and Between Intermune Pharmaceuticals, Inc. And Connetics Corporation June 23, 2000 (Superseding and Replacing the Amended and Restated Exclusive Sublicense Agreement of April 27, 1999) (February 27th, 2015)

THIS ASSIGNMENT AND OPTION AGREEMENT (the Agreement) is made effective and entered into as of June 23, 2000 (the Effective Date) by and between CONNETICS CORPORATION, a Delaware corporation, with a principal place of business at 3400 West Bayshore Road, Palo Alto, CA 94303 (Connetics), and INTERMUNE PHARMACEUTICALS, INC., a Delaware corporation, with a principal place of business at 1710 Gilbreth Road, Suite 301, Burlingame, CA 94010 (InterMune). Connetics and InterMune may be referred to herein as a Party or collectively as the Parties.

Vidara Therapeutics International Ltd – Assignment and Option Agreement by and Between Intermune Pharmaceuticals, Inc. And Connetics Corporation June 23, 2000 (Superseding and Replacing the Amended and Restated Exclusive Sublicense Agreement of April 27, 1999) (June 26th, 2014)

THIS ASSIGNMENT AND OPTION AGREEMENT (the Agreement) is made effective and entered into as of June 23, 2000 (the Effective Date) by and between CONNETICS CORPORATION, a Delaware corporation, with a principal place of business at 3400 West Bayshore Road, Palo Alto, CA 94303 (Connetics), and INTERMUNE PHARMACEUTICALS, INC., a Delaware corporation, with a principal place of business at 1710 Gilbreth Road, Suite 301, Burlingame, CA 94010 (InterMune). Connetics and InterMune may be referred to herein as a Party or collectively as the Parties.

Asterias Biotherapeutics, Inc. – EXCLUSIVE SUBLICENSE AGREEMENT Between GERON CORPORATION and ASTERIAS BIOTHERAPEUTICS, INC. (November 12th, 2013)

This EXCLUSIVE SUBLICENSE AGREEMENT (the "Agreement") is entered into as of October 1, 2013 (the "Effective Date") by and between Geron Corporation, a Delaware corporation having a principal place of business at 149 Commonwealth Drive, Menlo Park, California 94025 ("Geron"), and Asterias Biotherapeutics, Inc., a Delaware corporation having a principal place of business at 1301 Harbor Bay Parkway, Alameda, CA 94502 ("Licensee"). Geron and Licensee are each referred to individually herein as a "Party," and collectively as the "Parties."

EXCLUSIVE SUBLICENSE AGREEMENT Between GERON CORPORATION and ASTERIAS BIOTHERAPEUTICS, INC. (November 12th, 2013)

This EXCLUSIVE SUBLICENSE AGREEMENT (the "Agreement") is entered into as of October 1, 2013 (the "Effective Date") by and between Geron Corporation, a Delaware corporation having a principal place of business at 149 Commonwealth Drive, Menlo Park, California 94025 ("Geron"), and Asterias Biotherapeutics, Inc., a Delaware corporation having a principal place of business at 1301 Harbor Bay Parkway, Alameda, CA 94502 ("Licensee"). Geron and Licensee are each referred to individually herein as a "Party," and collectively as the "Parties."

Asterias Biotherapeutics, Inc. – EXCLUSIVE SUBLICENSE AGREEMENT Between GERON CORPORATION and BIOTIME ACQUISITION CORPORATION (August 13th, 2013)

This EXCLUSIVE SUBLICENSE AGREEMENT (the "Agreement") is entered into as of _____________, 2013 (the "Effective Date") by and between Geron Corporation, a Delaware corporation having a principal place of business at 149 Commonwealth Drive, Menlo Park, California 94025 ("Geron"), and BioTime Acquisition Corporation, a Delaware corporation having a principal place of business at 1301 Harbor Bay Parkway, Alameda, CA 94502 ("Licensee"). Geron and Licensee are each referred to individually herein as a "Party," and collectively as the "Parties."

Trimeris, Inc. – Exclusive Sublicense Agreement (May 7th, 2013)

THIS EXCLUSIVE SUBLICENSE AGREEMENT (the Agreement) is made and effective as of April 5, 2013 (the Effective Date) by and between Shire AG, a company organized under the laws of Switzerland, having a principal place of business at Business Park Terre-Bonne, Batiment A1, CH. De Terre Bonne 1,1262 Eysins, Switzerland (Shire), and Synageva BioPharma Corp., a Delaware corporation having a principal place of business at 128 Spring Street, Suite 520, Lexington, Massachusetts 02421, USA (Synageva). Shire and Synageva are referred to herein individually as a Party or collectively as the Parties.

Taylor & Martin Group Inc – Non-Exclusive Sublicense Agreement (August 30th, 2012)

This NON-EXCLUSIVE SUBLICENSE AGREEMENT (the Agreement), effective as of the Effective Date (herein defined below), is between TMG Founder Company (formerly named Taylor & Martin Group, Inc.) a Delaware corporation formed on March 24, 2011 (Sublicensor) and Taylor & Martin Group, Inc., a Delaware corporation formed on November 18, 2011 (Sublicensee).

Exclusive Sublicense Agreement (November 9th, 2011)
Amended and Restated Exclusive Sublicense Agreement (November 9th, 2011)
Confidential Treatment Requested. Information for Which Confidential Treatment Has Been Requested Is Omitted and Marked With [*******] or Otherwise Clearly Indicated. An Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission. Exclusive Sublicense Agreement (September 22nd, 2011)

This Exclusive Sublicense Agreement (hereinafter referred to as this Agreement), effective as of this December 12, 2005 (the Effective Date), is entered into by and between Ovamed GbmH & Co KG, a corporation duly incorporated under the laws of Germany and having a principal place of business at Kiebitzhorn 33-35, 22885 Barsbuttel, Germany (Ovamed) and Collingwood Pharmaceuticals, Inc., a corporation duly organized and existing under the laws of the State of Delaware having a principal place of business at 787 Seventh Avenue, 48th Floor, New York, New York 10019 (the Company).

Confidential Treatment Requested. Information for Which Confidential Treatment Has Been Requested Is Omitted and Marked With [*******] or Otherwise Clearly Indicated. An Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission. Exclusive Sublicense Agreement (September 9th, 2011)

This Exclusive Sublicense Agreement (hereinafter referred to as this Agreement), effective as of this December 12, 2005 (the Effective Date), is entered into by and between Ovamed GbmH & Co KG, a corporation duly incorporated under the laws of Germany and having a principal place of business at Kiebitzhorn 33-35, 22885 Barsbuttel, Germany (Ovamed) and Collingwood Pharmaceuticals, Inc., a corporation duly organized and existing under the laws of the State of Delaware having a principal place of business at 787 Seventh Avenue, 48th Floor, New York, New York 10019 (the Company).

Confidential Treatment Requested. Information for Which Confidential Treatment Has Been Requested Is Omitted and Marked With [*******] or Otherwise Clearly Indicated. An Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission. Exclusive Sublicense Agreement (July 15th, 2011)

This Exclusive Sublicense Agreement (hereinafter referred to as this Agreement), effective as of this December 12, 2005 (the Effective Date), is entered into by and between Ovamed GbmH & Co KG, a corporation duly incorporated under the laws of Germany and having a principal place of business at Kiebitzhorn 33-35, 22885 Barsbuttel, Germany (Ovamed) and Collingwood Pharmaceuticals, Inc., a corporation duly organized and existing under the laws of the State of Delaware having a principal place of business at 787 Seventh Avenue, 48th Floor, New York, New York 10019 (the Company).

Text Marked by [ * * *] Has Been Omitted Pursuant to a Request for Confidential Treatment and Was Filed Separately With the Securities and Exchange Commission. Exclusive Sublicense Agreement (March 31st, 2011)

This Exclusive Sublicense License Agreement (Agreement), dated as of May 28, 2010 (the Effective Date), is made by and between Targepeutics, Inc., a corporation organized under the laws of the State of Delaware (TI), having its principal office at 475 Governor Road, Hershey, PA 17033, and ImmunoCellular Therapeutics, Ltd., a Delaware corporation having its principal office at 21900 Burbank Boulevard, 3rd Floor, Woodland Hills, California 91367 (SUBLICENSEE).

Iaso Pharma Inc – Exclusive Sublicense Agreement (December 27th, 2010)

This Exclusive Sublicense Agreement (hereinafter referred to as this Agreement), effective as July 10th, 2007 (the Effective Date), is entered into by and between SANTEE BIOSCIENCES, INC., a Delaware corporation (Santee), having a place of business at 4365 Executive Drive, Suite 1500, San Diego, California 92121, and PACIFIC BEACH BIOSCIENCES, INC., a Delaware corporation (Pacific Beach), having a place of business at 4365 Executive Drive, Suite 1500, San Diego, California 92121.

Amendment No. 1 to Amended and Restated Exclusive Sublicense Agreement (November 19th, 2010)

This Amendment No. 1 (Amendment No. 1) to the Amended and Restated Exclusive Sublicense Agreement (Agreement) is entered into on November 1, 2010 (Effective Date) between BioMimetic Therapeutics, Inc. (BMTI), a Delaware corporation (formerly known as BioMimetic Pharmaceuticals, Inc.) and Luitpold Pharmaceuticals, Inc. (Luitpold), a New York corporation (each, individually, a Party and, collectively, the Parties).

Iaso Pharma Inc – Exclusive Sublicense Agreement (July 9th, 2010)

This Exclusive Sublicense Agreement (hereinafter referred to as this Agreement), effective as July 10th, 2007 (the Effective Date), is entered into by and between SANTEE BIOSCIENCES, INC., a Delaware corporation (Santee), having a place of business at 4365 Executive Drive, Suite 1500, San Diego, California 92121, and PACIFIC BEACH BIOSCIENCES, INC., a Delaware corporation (Pacific Beach), having a place of business at 4365 Executive Drive, Suite 1500, San Diego, California 92121.

Targeted Genetics Corporation – Amendment No. 4 to Exclusive Sublicense Agreement (August 12th, 2009)

THIS AMENDMENT NO. 4 (the Amendment) dated as of May 8, 2009 to the Exclusive Sublicense Agreement by and between Alkermes, Inc., a Pennsylvania corporation with its principal offices at 88 Sidney Street, Cambridge, MA 02139 (Alkermes), and Targeted Genetics Corporation, a Washington corporation with its principal offices at 1100 Olive Way, Suite 100, Seattle, Washington 98101 (Targeted),

TOM Online – LIMITED EXCLUSIVE SUBLICENSE AGREEMENT for DIELECTRIC WALL ACCELERATOR TECHNOLOGY Between TOMOTHERAPY INCORPORATED and COMPACT PARTICLE ACCELERATION CORPORATION (April 28th, 2008)

This sublicense agreement (Agreement) is effective on April 25, 2008 (the Effective Date) by and between TomoTherapy, Incorporated (TomoTherapy) under its exclusive license with Lawrence Livermore National Security, LLC as amended (LLNS), and Compact Particle Acceleration Corporation (LICENSEE). TomoTherapy and LICENSEE are referred to jointly as Parties. This Agreement and the resulting license are subject to overriding obligations to the Federal Government pursuant to the provisions of TomoTherapys exclusive license agreement with LLNS and LLNSs Contract No. DE-AC52-07NA27344 with the DOE for the operation of the Lawrence Livermore National Laboratory (LLNL).

Amended and Restated Exclusive Sublicense Agreement (March 12th, 2008)

This Amended and Restated Exclusive Sublicense Agreement (Agreement) is entered into on January 4, 2008 (Effective Date) between BioMimetic Therapeutics, Inc. (BMTI), a Delaware corporation (formerly known as BioMimetic Pharmaceuticals, Inc.) and Luitpold Pharmaceuticals, Inc. (Luitpold), a New York corporation (each, individually, a Party and, collectively, the Parties).

Reliant Pharmaceuticals – Exclusive Sublicense Agreement Between Reliant Pharmaceuticals, Llc and Novartis Ag (August 10th, 2007)

THIS SUBLICENSE AGREEMENT (this Agreement) dated as of the 11th day of March, 2003, by and between Novartis AG, a company incorporated under the laws of Switzerland, with a principal place of business located at Postfach 4002, Basel, Switzerland (hereinafter Novartis) and Reliant Pharmaceuticals, LLC, a Delaware limited liability company, with its principal place of business at 110 Allen Road, Liberty Corner, New Jersey 07938 (Reliant).

Non-Exclusive Sublicense Agreement (April 24th, 2007)

THIS NON-EXCLUSIVE SUBLICENSE AGREEMENT (Agreement) is made and entered into August 26, 2005 (the Effective Date) by and between Apath, L.L.C., a limited liability company of the State of Missouri, with a business address at 893 N. Warson Road, St. Louis, Missouri 63141 (Apath); and Pharmasset, Inc., a Delaware company, with a business address at 303A College Road East, Princeton, New Jersey 08540 (Pharmasset). Apath and Pharmasset are hereinafter referred to individually as a Party or collectively as Parties.

Targeted Genetics Corporation – Amendment No. 3 to Exclusive Sublicense Agreement (March 29th, 2007)

THIS AMENDMENT NO. 3 to the exclusive sublicense agreement (the "Amendment") is made and entered into as of March 9, 2007 by and between Alkermes, Inc., a Pennsylvania corporation with its principal offices at 88 Sidney Street, Cambridge, MA 02139 (hereinafter referred to as "Alkermes"), and Targeted Genetics Corporation, a Washington corporation with its principal offices at 1100 Olive Way, Suite 100, Seattle, Washington 98101 (hereinafter referred to as "Targeted").

ANI Pharmaceuticals, Inc. – Exclusive Sublicense Agreement (March 27th, 2007)

This AGREEMENT (Agreement), dated November 7, 2006 (the Effective Date), is made by and between BioSante Pharmaceuticals, Inc., 111 Barclay Boulevard, Lincolnshire, IL 60069 (BPA), and Bradley Pharmaceuticals, Inc., 383 Route 46 West, Fairfield, New Jersey 07004-2402 (Company).

Telomolecular Corp – EXCLUSIVE SUBLICENSE AGREEMENT UNeMed Corporation and Telomolecular Corp. Effective January 16, 2006 Exclusive Sublicense Agreement (January 16th, 2007)

This Exclusive Sublicense Agreement, effective January 16, 2006 ("Effective Date"), is made between UNeMed Corporation ("UNeMed") and Telomolecular Corp. ("Licensee").

Somanta Pharmaceuticals Inc. – Side Amendment to Patent and Know-How Exclusive Sublicense Agreement (December 11th, 2006)

This Side Amendment to patent and know-how exclusive sublicense Agreement (the Side Agreement) is entered into Friday, November 3, 2006 (Effective Date) by and among Immunodex, Inc., a California corporation having an address at 1230 H Street, Eureka, California, 95501 (Immunodex); The Cancer Research Institute of Contra Costa having an address at 1230 H Street, Eureka, CA 95501 (CRICC); and Somanta Incorporated (Somanta) having business addresses at 19200 Von Karman Avenue, Suite 400, Irvine, CA 92612 USA and 80 Harley Street, London, W1G 7HB, United Kingdom.

Ocata Therapeutics, Inc. – Exclusive Sublicense Agreement (May 15th, 2006)

This Exclusive Sublicense Agreement (Agreement) is made and entered into as of March 29, 2006 (the Effective Date), by and between TranXenoGen, Inc., a Delaware corporation with offices located at 800 Boston Turnpike Rd, Shrewsbury, Massachusetts 01545 (TXG), and Advanced Cell Technology, Inc., a Delaware corporation with offices located at 1201 Harbor Bay Parkway, Suite 120, Alameda, California 94502 (Licensee or ACT) (TXG and Licensee sometimes hereinafter referred to as the parties, or individually as a party). As set forth below, Brandeis University (the University) agrees to be bound by certain provisions of this Agreement.

Exclusive Sublicense Agreement (May 10th, 2006)
Exclusive Sublicense Agreement (May 9th, 2006)
Non-Exclusive Sublicense Agreement (May 8th, 2006)

THIS NON-EXCLUSIVE SUBLICENSE AGREEMENT (Agreement) is made and entered into August 26, 2005 (the Effective Date) by and between Apath, L.L.C., a limited liability company of the State of Missouri, with a business address at 893 N. Warson Road, St. Louis, Missouri 63141 (Apath); and Pharmasset, Inc., a Delaware company, with a business address at 303A College Road East, Princeton, New Jersey 08540 (Pharmasset). Apath and Pharmasset are hereinafter referred to individually as a Party or collectively as Parties.

Amendment No. 1 to Exclusive Sublicense Agreement (February 10th, 2006)
Exclusive Sublicense Agreement (February 10th, 2006)
Ocata Therapeutics, Inc. – NONEXCLUSIVE SUBLICENSE AGREEMENT Between CYAGRA, INC., ADVANCED CELL TECHNOLOGY, INC., and GOYAIKE, S.A. (May 23rd, 2005)

This Nonexclusive Sublicense Agreement (the Agreement) is made and entered into as of this 20th day of November, 2001 (the Effective Date) by and between Cyagra, Inc., a Delaware corporation with a place of business at One Innovation Drive, Worcester, Massachusetts 01605 (CYAGRA), Advanced Cell Technology, Inc., a Delaware corporation with a place of business at One Innovation Drive, Worcester, Massachusetts 01605 (ACT INC), A.C.T. Group, Inc., a Delaware corporation with a place of business at One Innovation Drive, Worcester, Massachusetts 01605(ACT GROUP, together with CYAGRA, ACT INC and respective current and future Affiliates, the Licensors) and Goyaike, S.A., an Argentina corporation with a place of business at Av, do Mayo 701, Piso 16, 1084 Buenos Aires, Argentina (GOYAIKE, together with Licensors, the parties). As set forth below, the University of Massachusetts (the University) has agreed to be bound by certain provisions of this Agreement.